Welcome
Meeting Highlights

- **Plenaries**
  - Community: Sunday
  - HPTN: Monday
  - Laboratory: Tuesday
  - Joint HPTN-IMPAACT: Wednesday
- **Protocol teams** – throughout the meeting
- **HPTN Scholars presentation**: Monday
Meeting Highlights II

- Poster session and gathering: Tuesday
- Executive Committee, Scientific Advisory Group, and Committee and Working Groups
- Community Workshop
- DAIDS Training
# Current HPTN Scientific Agenda

<table>
<thead>
<tr>
<th>Biomedical</th>
<th>Behavioral</th>
<th>Structural</th>
<th>Integrated Strategies</th>
</tr>
</thead>
<tbody>
<tr>
<td>HPTN 052</td>
<td>HPTN 061*</td>
<td>HPTN 043*</td>
<td>HPTN 065</td>
</tr>
<tr>
<td>HPTN 058*</td>
<td>HPTN 062*</td>
<td>HPTN 068</td>
<td>HPTN 071@</td>
</tr>
<tr>
<td>HPTN 066</td>
<td>HPTN 063</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HPTN 067</td>
<td>HPTN 064*</td>
<td></td>
<td>HPTN 074@</td>
</tr>
<tr>
<td>HPTN 069</td>
<td></td>
<td></td>
<td>HPTN 075@</td>
</tr>
<tr>
<td>HPTN 073</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HPTN 076@</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* * completed
@ * in development
<table>
<thead>
<tr>
<th>Variable</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>HIV Status</td>
<td>HIV negative, acute infection, established HIV infection</td>
</tr>
<tr>
<td>Populations</td>
<td>Adolescents, MSM, women, pregnant women, IDU, communities</td>
</tr>
<tr>
<td>Interventions</td>
<td>Behavioral, HIV testing, PrEP, ART, VMMC, substitution/antagonist therapy, financial incentives, integrated strategies</td>
</tr>
<tr>
<td>Types of Studies</td>
<td>Observational, individual randomized, site randomized, community randomized, implementation science</td>
</tr>
</tbody>
</table>
HPTN 068: Effects of Cash Transfer for the Prevention of HIV in Young South African Women
## Breadth of the HPTN Portfolio

<table>
<thead>
<tr>
<th>Variable</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>HIV Status</td>
<td>HIV negative, acute infection, established HIV infection</td>
</tr>
<tr>
<td>Populations</td>
<td>Adolescents, MSM, women, pregnant women, IDU, communities</td>
</tr>
<tr>
<td>Interventions</td>
<td>Behavioral, HIV testing, PrEP, ART, VMMC, substitution/antagonist therapy, financial incentives, integrated strategies</td>
</tr>
<tr>
<td>Types of Studies</td>
<td>Observational, individual randomized, site randomized, community randomized, implementation science</td>
</tr>
</tbody>
</table>
HPTN 068

- A Phase III individually randomized design for assessing conditional cash transfers

- About 2,500 young women needed to enroll (2,536 were actually randomized and enrollment is complete)

- South Africa
HPTN 068 Study Groups

• Structural Intervention Arm
  – Young woman and her parents receive monthly cash transfer payments conditional on the young woman’s school attendance (must be ≥ 80% of in-session days)

• Control Arm
  – No payments given to the participant
HPTN 065: Feasibility of Test, Link to Care and Treat (TLC-Plus) in the US
## Breadth of the HPTN Portfolio

<table>
<thead>
<tr>
<th>Variable</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>HIV Status</td>
<td>HIV negative, acute infection, established HIV infection</td>
</tr>
<tr>
<td>Populations</td>
<td>Adolescents, MSM, women, pregnant women, IDU, sites</td>
</tr>
<tr>
<td>Interventions</td>
<td>Behavioral, HIV testing, PrEP, ART, VMMC, substitution/antagonist therapy, financial incentives, integrated strategies</td>
</tr>
<tr>
<td>Types of Studies</td>
<td>Observational, individual randomized, site randomized, community randomized, implementation science</td>
</tr>
</tbody>
</table>
HPTN 065
Test Link to Care Plus Treat (TLC-Plus)
PURPOSE
To evaluate the feasibility of an enhanced community-level HIV test, link-to-care plus treat strategy in the U.S.
HPTN 065 (TLC-Plus)

Test
- Testing
- HIV Positive
- Positive Prevention
- Adopt safer behaviors

Enroll in Care
- Initiation of ART
- Treat
- Adherence to ART
- Maintain viral suppression

Linkage to care

Decrease in HIV Transmission
HPTN 065 Study Design

**HIV Testing & Linkage to Care**

- Expand HIV Testing
  - Social Mobilization
  - Universal offer of testing in ED/hospital admission
- HIV Testing Sites
  - 38 Randomized HIV Test Sites to link HIV positives
    - Financial incentive plus SOC
    - Standard of care (SOC)

**HIV Treatment**

- HIV Care Sites
  - 39 Randomized HIV Care Sites
    - Financial incentive plus SOC
    - Standard of care (SOC)

**Prevention for Positives**

- Select HIV Care Sites
  - Individual randomization of 660 patients in 2 communities
    - CARE plus Standard of Care
    - Standard of Care
# Current HPTN Scientific Agenda

<table>
<thead>
<tr>
<th>Biomedical</th>
<th>Behavioral</th>
<th>Structural</th>
<th>Integrated Strategies</th>
</tr>
</thead>
<tbody>
<tr>
<td>HPTN 052</td>
<td>HPTN 061*</td>
<td>HPTN 043*</td>
<td>HPTN 065</td>
</tr>
<tr>
<td>HPTN 058*</td>
<td>HPTN 062*</td>
<td>HPTN 068</td>
<td>HPTN 071@</td>
</tr>
<tr>
<td>HPTN 066</td>
<td>HPTN 063</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HPTN 067</td>
<td>HPTN 064*</td>
<td></td>
<td>HPTN 074@</td>
</tr>
<tr>
<td>HPTN 069</td>
<td></td>
<td></td>
<td>HPTN 075@</td>
</tr>
<tr>
<td>HPTN 073</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HPTN 076@</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* completed  
@ in development
Pre-exposure Prophylaxis (PrEP)
Pre Exposure Prophylaxis (PrEP) HPTN Studies

- HPTN 066: PK for intermittent PrEP
- HPTN 067: PK and behavioral study of intermittent PrEP in MSM and women
- HPTN 069: Maraviroc for PrEP in MSM and women

- HPTN 073: Uptake of PrEP by Black MSM
- HPTN 076: Safety of a long acting injectable drug (TMC278LA) for PrEP in women
HPTN 073: PrEP Adherence and Uptake Among BMSM in Two U.S. Cities
## Breadth of the HPTN Portfolio

<table>
<thead>
<tr>
<th>Variable</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>HIV Status</td>
<td>HIV negative, acute infection, established HIV infection</td>
</tr>
<tr>
<td>Populations</td>
<td>Adolescents, MSM, women, pregnant women, IDU, communities</td>
</tr>
<tr>
<td>Interventions</td>
<td>Behavioral, HIV testing, PrEP, ART, VMMC, substitution/antagonist therapy, financial incentives, integrated strategies</td>
</tr>
<tr>
<td>Types of Studies</td>
<td>Observational, individual randomized, site randomized, community randomized, implementation science</td>
</tr>
</tbody>
</table>
Purpose

To assess the initiation, acceptability, safety, and feasibility of PrEP for Black men who have sex with men (BMSM) in three U.S. cities utilizing client-centered care coordination (C4) models.
Design

- An open label demonstration study with PrEP + C4 model.
- A subset of participants will also be recruited to participate in qualitative interviews about facilitators and barriers regarding PrEP
- A total of 225 participants, 75 participants at three U.S. sites
- Once daily oral emtricitabine 200 mg / tenofovir 300 mg (FTC/TDF) combined with C4.
At-a-Glance poster

Located at the HPTN Registration B outside the Thurgood Marshall Ballroom in the Foyer (upper level).

### HPTN 2013 Annual Meeting

#### Day-at-a-Glance

**Tuesday, May 7th**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00 am – 8:30 am</td>
<td>HPTN Breakfast</td>
<td>Madison A</td>
</tr>
<tr>
<td>7:00 am – 10:00 am</td>
<td>HPTN 071 CGW Meeting</td>
<td>Thurgood Marshall East</td>
</tr>
<tr>
<td>8:00 am – 10:00 am</td>
<td>Network Laboratory Plenary</td>
<td>Thurgood Marshall East</td>
</tr>
<tr>
<td>8:00 am – 12:00 pm</td>
<td>HPTN Black Caucus Meeting</td>
<td>Tyler</td>
</tr>
<tr>
<td>9:00 am – 5:00 pm</td>
<td>DAIDS Training Resources Drop In Room</td>
<td>Taft</td>
</tr>
<tr>
<td>9:30 am - 10:30 am</td>
<td>HPTN Break</td>
<td>Thurgood Marshall Foyer</td>
</tr>
<tr>
<td>9:30 am - 11:30 am</td>
<td>HPTN 058 Meeting</td>
<td>Johnson</td>
</tr>
<tr>
<td>10:00 am – 12:00 pm</td>
<td>HPTN 068 Meeting</td>
<td>Nathan Hale</td>
</tr>
<tr>
<td>10:30 am – 12:30 pm</td>
<td>HPTN 067/ADAPT Meeting</td>
<td>Thurgood Marshall East</td>
</tr>
<tr>
<td>10:30 am – 12:30 pm</td>
<td>HPTN 052 Team Meeting</td>
<td>Thurgood Marshall South</td>
</tr>
<tr>
<td>10:30 am – 12:30 pm</td>
<td>HPTN 071 Meeting with IAG</td>
<td>Madison A</td>
</tr>
<tr>
<td>10:00 am – 2:30 pm</td>
<td>HPTN 063 Qualitative Team Meeting</td>
<td>Taylor</td>
</tr>
<tr>
<td>10:30 am – 3:30 pm</td>
<td>HPTN 064 Publications Meeting</td>
<td>Embassy</td>
</tr>
<tr>
<td>11:30 am – 1:00 pm</td>
<td>HPTN Lunch</td>
<td>Thurgood Marshal NW</td>
</tr>
<tr>
<td>12:00 pm – 3:00 pm</td>
<td>HPTN MSM Science Committee Meeting</td>
<td>Madison B</td>
</tr>
<tr>
<td>12:30 pm – 3:30 pm</td>
<td>HPTN Adolescent-at-Risk Scientific Committee</td>
<td>Nathan Hale</td>
</tr>
<tr>
<td>1:30 pm – 3:00 pm</td>
<td>HPTN 067/ADAPT Qualitative Team</td>
<td>Johnson</td>
</tr>
<tr>
<td>1:30 pm – 3:00 pm</td>
<td>HPTN 071 Study Progress and Q&amp;A with Funders and Partners</td>
<td>Thurgood Marshall East</td>
</tr>
<tr>
<td>1:30 pm – 3:00 pm</td>
<td>HPTN 071 IAG Meeting (closed for IAG only)</td>
<td>Madison A</td>
</tr>
<tr>
<td>2:30 pm – 3:30 pm</td>
<td>HPTN Break</td>
<td>Thurgood Marshall Foyer</td>
</tr>
<tr>
<td>3:00 pm – 4:30 pm</td>
<td>HPTN 071/IAG Debrief</td>
<td>Madison A</td>
</tr>
<tr>
<td>3:00 pm – 6:00 pm</td>
<td>HPTN Scholars’ Meeting</td>
<td>Tyler</td>
</tr>
<tr>
<td>3:00 pm – 6:00 pm</td>
<td>HPTN 063 Team meeting</td>
<td>Thurgood Marshall South</td>
</tr>
<tr>
<td>3:30 pm – 5:30 pm</td>
<td>HPTN Behavioral Social Sciences Meeting</td>
<td>Madison B</td>
</tr>
<tr>
<td>4:30 pm – 6:00 pm</td>
<td>HPTN 071 Team Meeting</td>
<td>Thurgood Marshall East</td>
</tr>
<tr>
<td>7:00 pm – 9:00 pm</td>
<td>Networks Gathering &amp; Poster Session</td>
<td>Thurgood Marshall Ballroom</td>
</tr>
<tr>
<td>8:00 pm – 10:00 pm</td>
<td>HPTN/IMPAACT PMTCT Meeting</td>
<td>Taylor</td>
</tr>
</tbody>
</table>
Presentations of Third Year HPTN Scholar Projects

**Today**: 4:00pm – 6:00pm in Thurgood Marshall East

- Introductions to findings will be presented during the afternoon plenary

Dr. Andres Bedoya  
Dr. Oni Blackstock  
Dr. Grace Hall  
Dr. Sophia Hussen  
Dr. Brooke Montgomery  
Dr. Malika Roman Isler  
Dr. Chevette Williams
The DAIDS Training Resources Drop-in Room

What Can I Do There?

• Ask your questions about DAIDS electronic systems, like
  – Protocol Registration and DPRS
  – AE reporting and DAERS

Access and complete e-learning courses like:
  ▪ Critical Events Policy and Manual Training
  ▪ Introduction to the US FDA Inspection Process
  ▪ Good Clinical Lab Practice (GCLP) Refresher
  ▪ HIV Research Counseling and Testing
    ...and much more!
Will there be someone there to help me?

A specialist will help you with...

– Setting up access to unlimited online training (DAIDS Learning Management System)
– Hands-on practice
– Live demonstrations
DAIDS Training Drop-in Room

Drop by the Taft Room any time:

• **Monday**, 06 May 2013, 3:30 PM – 5:00 PM
• **Tuesday**, 07 May 2013, 9:00 AM – 5:00 PM

*To learn more, pick up a flyer from the table near registration.*
Got Questions? DAIDS RSC has the answers.

The DAIDS Regulatory Support Center team will be answering your questions at the HPTN 2013 Annual Meeting

Don’t miss this great opportunity to get guidance from the DAIDS RSC Team at our Information Booth:

- **Where:** Thurgood Marshall’s Registration B Foyer
- **When:** May 7, 2013 9:00 AM to 5:00 PM

**HPTN 2013 Annual Meeting**
Washington, DC
May 3 - 8, 2013

**Location:**
Washington Marriott Wardman Park Hotel
2660 Woodley Park Road NW
Washington, DC 20008

**Event Website:**
http://www.hptn.org

**DAIDS RSC Website:**
http://rsc.tech-res.com

You can submit questions ahead of time via email to DAIDSRSCMgers@tech-res.com.

This project is funded by the Division of AIDS (DAIDS), National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under contract No. HHSN272201000013C, entitled DAIDS Regulatory Support Center (RSC).
HPTN Publications 2012-2013

HIV JOURNAL PUBLICATIONS AND NIH PUBLIC ACCESS POLICY

Are You Compliant with NIH Public Access Policy?

The NIH Public Access Policy ensures that the public has access to the published results of NIH-funded research. It requires scientists to submit final peer-reviewed journal manuscripts that arise from NIH-funded projects to the digital archive PubMed Central upon acceptance for publication. To achieve this, advanced search capabilities for searching the global public health community, the policy requires that these papers be accessible to the public on PubMed Central 12 months after publication.

What is the connection between PMC and the NIH Public Access Policy?

Since its creation in 2003, PArch has served as a free digital archive of full-text biomedical and behavioral science journal literature at the U.S. National Institutes of Health (NIH). Beginning in 2005, PArch has also been the designated repository for papers submitted in accordance with the NIH Public Access Policy for those that fall under public access compliance rules.

Are you compliant with NIH Public Access Policy?

The NIH Public Access Policy ensures that the public has access to the published results of NIH-funded research. It requires scientists to submit final peer-reviewed journal manuscripts that arise from NIH-funded projects to the digital archive PubMed Central upon acceptance for publication. To achieve this, advanced search capabilities for searching the global public health community, the policy requires that these papers be accessible to the public on PubMed Central 12 months after publication.

What is the connection between PMC and the NIH Public Access Policy?

Since its creation in 2003, PArch has served as a free digital archive of full-text biomedical and behavioral science journal literature at the U.S. National Institutes of Health (NIH). Beginning in 2005, PArch has also been the designated repository for papers submitted in accordance with the NIH Public Access Policy for those that fall under public access compliance rules.
What’s New in the HPTN?

HPTN: A Look Back and the Way Forward

At this juncture in the history of the HIV Prevention Trials Network (HPTN), we look back with pride on our many accomplishments. Since the Network’s inception in 1993, we continue to evolve, as prevention science has evolved, but remain steadfast in our resolve to discover and develop new and innovative interventions and strategies to reduce the acquisition and transmission of HIV. This mission is evident in our completed, ongoing, and proposed research agendas.

A watershed moment for HPTN’s research success was realized in 2011 when the HPTN 052 study showed that providing early antiretroviral therapy (ART) among serodiscordant couples reduced sexual transmission of HIV by 96 percent. HPTN 052 was named Science magazine’s breakthrough of the year and was recognized as “a game changer” for HIV prevention. More recently, HPTN 043, another landmark study, demonstrated that community-based HIV testing was associated with an increase in testing rates and in detection of HIV infected individuals. (Full article on page 2.)

The success of these studies paved the way for expanding HPTN’s portfolio to include the use of testing for and treatment of HIV infection as part of a comprehensive combination HIV prevention strategy. HPTN 071 (PopART) is evaluating the impact of an integrated strategy on HIV incidence at a community level in Zambia and South Africa. The experimental intervention package will include universal HIV counseling and testing through house-to-house testing.

continued on page 3

Making Progress

HPTN JAIDS Supplement

The HPTN is excited to announce that it is sponsoring a special supplement to Journal of Acquired Immune Deficiency Syndromes (JAIDS) to be published in conjunction with the IAS 2013 Conference. The supplement titled, State of the ART HIV Prevention, will feature 23 manuscripts devoted to diverse aspects of HIV prevention with a critical analysis of science breakthroughs, promises, and challenges. The supplement will be available online at www.jaids.org and www.hptn.org beginning June 26, 2013. The supplement is funded by NIAID and Office of Global AIDS Coordinator.

HPTN at IAS 2013

The HPTN is also proud to announce that four of its abstracts have been accepted at IAS 2013. HPTN scholars are well represented with three abstracts:

- A Qualitative Analysis of HIV Testing Patterns among Black Men who have Sex with Men In Atlanta, Georgia, USA (HPTN 061)

- Prevalence and HIV Risk-Related Correlates of Emotional, Physical, and Sexual Violence among Women at Risk for HIV in the United States: Data from HPTN 064 (The WDHEN HIV Prevalence Study)
STATE OF THE ART
HIV PREVENTION

A JAIDS supplement sponsored by the HIV Prevention Trials Network (HPTN)

Guest Editors:
Wafaa M. El-Sadr, MD, MPH, MPA
Myron S. Cohen, MD
Nirupama D. Sista, MSc, PhD
David Serwadda, MD
JAIDS Supplement, July 2013

- HIV prevention: great achievements, more challenges ahead
- Acute and Early HIV Infection
- Expanding HIV Testing
- Pre-Exposure Prophylaxis
- Prevention of HIV among Adolescents
- Research to Decrease HIV Transmission in Men who have Sex with Men
- Male Circumcision
- An Expanded Behavioral Paradigm for Prevention of HIV-1 Infection
- Preventing HIV infection in women
- Topical Microbicides – What’s New?
- Social and behavioral sciences in trials of biomedical HIV prevention interventions
- Substance Users and Future Directions
JAIDS supplement, July 2013--II

- ART for Prevention of HIV and Tuberculosis
- Elimination of new pediatric HIV infections
- Study Design Considerations for Evaluating PrEP efficacy
- Combination HIV Prevention for MSM in the Americas and heterosexual African populations
- Antiretroviral Pharmacology in Mucosal Tissues
- Future of Phylogeny in Prevention
- Cross-Sectional HIV Incidence Estimation
- Ethics and Pre-Exposure Prophylaxis for HIV-infection
- Community Perspectives on Prevention: Priorities for a New Era
- The HPTN 071/PopART study in South Africa and Zambia
- Translational Research Insights from Completed HIV Vaccine Efficacy Trials
Acknowledgements

- David Burns, Katherine Davenny; Carl Dieffenbach, Michael Gilbreath, Diane Rausch, Sheryl Zwerski
- HPTN Executive Committee and leadership group
- Scientific committee and working groups leadership and members
- Investigators, staff and community representatives at HPTN sites

Sponsored by NIAID, NIDA, NIMH under Cooperative Agreement # UM1 AI068619 and all the cooperative agreements for SDMC, NL, and CTUs

Additional support: OGAC, BMGF